3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
4
Completed
3
Withdrawn
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Neoplasms
2
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pinealoma
1
Pancreatic Cancer Metastatic
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Myeloproliferative Disorders
1
Medulloblastoma
1
Leukemia, Myelomonocytic, Chronic
1
Histiocytosis, Langerhans-Cell
1
Ependymoma
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Radiotherapy
11
pembrolizumab
10
Nivolumab
10
Doxorubicin
10
Magnetic Resonance Spectroscopy
9
Specimen Handling
8
Ipilimumab
7
Cyclophosphamide
7
Biopsy
7
X-Rays
6
Radiation
5
Phantoms, Imaging
5
Ifosfamide
5
talimogene laherparepvec
4
cabozantinib
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
tazemetostat
3
selpercatinib
3
pazopanib
3
liposomal doxorubicin
3
Temozolomide
3
Etoposide
3
ulixertinib
2
tislelizumab
2
tipifarnib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Sarcoma
×
Celecoxib
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled